What's on the Horizon for New Vaccines?

National Advisory Committee on Immunization. Statement on human papillomavirus vaccine. Canada Communicable Disease Report 2007; 33 (ACS-2): 1–32. Available: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07pdf/acs33-02.pdf (accessed March 14, 2007)

Menactra Product Monograph. Sanofi Pasteur Limited. August 2006; p. 13. Available: www.vaccineshoppecanada.com/secure/pdfs/ca/menactra_e.pdf (accessed March 14, 2007)

Health Canada. Canadian Immunization Guide. 7th ed. Ottawa: Health Canada; 2006. p. 237–50. Available: www.phac-aspc.gc.ca/publicat/cig-gci/index.html (accessed March 19, 2007)

Snape MD Pollard AJ . Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005; 5 (1): 21–30

Guidelines for the prevention and control of meningococcal disease. Canada Communicable Disease Report 2005 Suppl;31S1

Davis RL . Guillain-Barré syndrome (GBS) among recipients of meningococcal conjugate vaccine (MCV4, Menactra®). Update Oct. 2006-Jan. 2007. Presentation to the Advisory Committee on Immunization Practices (ACIP), February 2007, Atlanta, Georgia. Available: www.cdc.gov/nip/ACIP/slides/feb07/07-izsafety-1-davis.pdf (accessed March 14, 2007)

Update: Guillain-Barré syndrome among recipients of Menactra® meningococcal conjugate vaccine, United States, June 2005–Sept 2006. Morb Mortal Wkly Rep 2006; 55 (41);1120–4

Gardasil Product Monograph. Merck Frosst. July 2006. Available: www.merckfrosst.ca/mfcl/en/corporate/products/gardasil.html (accessed March 22, 2007)

Villa LL Costa RL Petta CA High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95 (11): 1459–66

RotaTeq Product Monograph. Merck Frosst. August 2006. Available: www.merckfrosst.ca/mfcl/en/corporate/products/rotateq.html (accessed March 22, 2007)

Glass RI Bresee JS Turcios R Rotavirus vaccines: targeting the developing world. J Infect Dis 2005; 192 Suppl 1: S160–6

Waters V Ford-Jones EL Petric M Etiology of community-acquired pediatric viral diarrhea: a prospective longitudinal study in hospitals, emergency departments, pediatric practices and child care centers during the winter rotavirus outbreak, 1997 to 1998. Pediatr Infect Dis J 2000; 19 (9): 843–8

Vesikari T Matson DO Dennehy P Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354 (1): 23–33

Haber P Baggs J Patel M Summary of Rotateq vaccine reports to VAERS, 3/1/06-2/15/07. Presentation to the Advisory Committee on Immunization Practices (ACIP) February 2007, Atlanta, Georgia. Available: www.cdc.gov/nip/ACIP/slides/feb07/02-rotavirus-3-patel_haber.pdf (accessed March 14, 2007)

Harper DM Franco EL Wheeler CM HPV Vaccine Study Group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006; 367 (9518): 1247–55

Harper DM Franco EL Wheeler C Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004; 364 (9447): 1757–65

Ruiz-Palacios GM Perez-Schael I Velazquez FR Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354 (1): 11–22